No Picture
News

Evofem Biosciences’ CEO Saundra Pelletier Named to PharmaVOICE100 – The Most Inspiring People in Life Sciences

SAN DIEGO, Aug. 3, 2020 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the PharmaVOICE 100 Most Inspiring People, an annual list of the 100 most innovative, influential and inspir… […]

No Picture
News

Data Affirming Biocept’s Target Selector(TM) Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program

Target Selector(TM) platform shown to be potentially more sensitive than standard-of-care cytology in detecting mutations of brain metastases in cerebrospinal fluid

SAN DIEGO, May 29, 2020 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading comme… […]

No Picture
News

DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS

-DTx was one of 8 grantees selected out of more than 100 academic and company applicants worldwide-

SAN DIEGO, May 13, 2020 /PRNewswire/ — DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat … […]

No Picture
News

Neurana Pharmaceuticals Announces Publication of a Driving Study Demonstrating the Effects of Tolperisone

SAN DIEGO, May 12, 2020 /PRNewswire/ — Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced the publication of a driving study which demonstrates the tolerabili… […]

No Picture
News

Neurocrine Biosciences Announces New Data Published from the Largest Real-World Screening Study, RE-KINECT, Demonstrating that Movements Consistent with Tardive Dyskinesia Occur Frequently and Can Reduce Quality of Life in Patients with Psychiatric Disorders

— Results from Real-World Screening Study Highlight Importance of Raising Awareness of Tardive Dyskinesia During Mental Health Month — 75% of Patients with Possible Tardive Dyskinesia Affirmed Feeling Self-Conscious or Embarrassed About Involuntary … […]

No Picture
News

Randomized Controlled Trial Results Published in ‘Spine’ Demonstrate Efficacy of NuVasive Attrax® Putty in Posterolateral Lumbar Fusion

– Attrax Putty is now the first and only ceramic bone graft substitute supported by Level I evidence to demonstrate non-inferior fusion performance compared to autograft(1) –

SAN DIEGO, March 10, 2020 /PRNewswire/ –?NuVasive, Inc. (NASDAQ: NUVA), t… […]